Hepatitis/MASH

Liver damage is the bane of HIV-infected patients' existence.

A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.

Cancer rates significantly greater compared with non-infected individuals.

Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.

Cirrhosis-related death rates drop across all age brackets.

Therapy shows promise in treatment of hepatitis C genotype-1 mono-infected patients.

Raplixa reduces time needed to stop bleeding during surgery.

Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.

Merck's once-daily treatment regimen of grazoprevir and elbasvir may bring added competition to HCV drug market.

Despite increases in liver cirrhosis hospitalizations over the years, the cirrhotic inpatient death rate has dropped 41%.

An antiviral and anti-cancer drug combination was 100% effective in preclinical trials.

HIV-infected men may be more sensitive to alcohol's effects.

Record number of orphan drugs approved in 2014.

Orphan drugs and breakthrough therapies last year comprised the highest number of new medications approved since 2001.

Co-administration of amiodarone with simeprevir and sofosbuvir combination is not recommended.

The FDA approved Triumeq (abacavir, dolutegravir, and lamivudine) tablets for the treatment of HIV-1 infection in patients without the HLA-B*5701 allele.

Pharmacists provide medication expertise that is essential to both the patient and the health care team in the treatment of hepatitis C.

High cost of new drugs make treating even the sickest inmates impractical.

CCZ impairs the ability of the virus to enter human liver cells.

Treating prisoners for hepatitis C virus can be a costly nightmare, straining prisons' pharmacy and health care budgets.

Combination fast-tracked for approval to treat chronic HCV GT1 infection in end-stage renal disease patients on hemodialysis.

The FDA has granted 2 breakthrough therapy designations to grazoprevir/elbasvir.

HIV patients need to have undetectable viral load to undergo procedure.

Completion rates remain lower than rates reported in clinical trials.

Specialty drugs comprise 28% of total drug costs from just 1% of claims.